Loading viewer...
investor_presentation
Format: PDF investor_presentation
Next Science Limited presents its FY22 financial results and business overview as of February 28, 2023. The company develops proprietary XBIO technology to reduce biofilm-based infections across wound and surgical applications, with a TAM exceeding US$12.5 billion and 47 patents. The presentation outlines product distribution strategies, revenue growth of 462,000 episodes of care (+80% YoY), and expansion plans within the advanced wound care market.
UHREIT 2024 Investor Presentation US Grocery-Anchored Shopping Center
investor_presentationinvestor_presentation
42 Pages
UHREIT (United Hampshire US REIT)